U.S. markets open in 4 hours 50 minutes

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
82.20+0.55 (+0.67%)
At close: 4:00PM EDT
81.94 -0.26 (-0.32%)
Pre-Market: 04:32AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close81.65
Open82.29
Bid0.00 x 800
Ask0.00 x 800
Day's Range82.15 - 82.89
52 Week Range63.22 - 84.94
Volume433,856
Avg. Volume896,776
Market Cap190.075B
Beta (5Y Monthly)0.32
PE Ratio (TTM)27.84
EPS (TTM)2.95
Earnings DateN/A
Forward Dividend & Yield1.84 (2.26%)
Ex-Dividend DateMar 26, 2021
1y Target Est82.91
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-18% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Novo Nordisk A/S – Share repurchase programme
    GlobeNewswire

    Novo Nordisk A/S – Share repurchase programme

    Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 21 June 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginnin

  • Here's Why Altimmune Stock Is Surging Today
    Motley Fool

    Here's Why Altimmune Stock Is Surging Today

    Shares of Altimmune (NASDAQ: ALT), a clinical-stage biopharmaceutical company, are on the move following a positive clinical readout. Investors excited about the company's potential new weight loss drug drove the stock 23% higher as of 12:34 p.m. on Wednesday. Altimmune's weight loss drug candidate, ALT-801, is a GLP-1 receptor agonist that also activates glucagon receptors.

  • The Zacks Analyst Blog Highlights: Microsoft, Nike, Novo Nordisk, Caterpillar and General Electric
    Zacks

    The Zacks Analyst Blog Highlights: Microsoft, Nike, Novo Nordisk, Caterpillar and General Electric

    The Zacks Analyst Blog Highlights: Microsoft, Nike, Novo Nordisk, Caterpillar and General Electric